ORIGINAL RESEARCH article

Front. Neurol., 21 October 2025

Sec. Stroke

Volume 16 - 2025 | https://doi.org/10.3389/fneur.2025.1683753

Predictors of unplanned hospital readmissions and emergency department revisits in patients with acute ischemic stroke

  • 1. Department of Neurology, Emory University, Atlanta, GA, United States

  • 2. Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, United States

Article metrics

View details

1,5k

Views

226

Downloads

Abstract

Objectives:

We aim to identify factors associated with emergency department (ED) revisits and hospital readmissions after acute ischemic stroke (AIS) diagnosis and to determine if early outpatient follow-up can reduce readmissions.

Methods:

We retrospectively identified all AIS patients discharged from a hospital network, from October 1, 2022 to March 31, 2024. Baseline characteristics, inpatient metrics and post-discharge outpatient follow-up were assessed to identify factors associated with ED revisits and readmissions to the healthcare system within 90-days.

Results:

Of 1,973 patients, 464 (23.5%) had ED visits within 90 days and 263 (13.3%) had hospital readmission within 90 days. The median age was 68 [IQR 58, 77]. In multiple logistic regression analyses, factors independently associated with 90-day ED visit were history of heart failure (HF) (OR 1.46, 95% CI 1.11–1.93; p = 0.007), diabetes mellitus (DM) (OR 1.41, 95% CI 1.12–1.77; p = 0.003), atrial fibrillation (AF) (OR 1.47, 95% CI 1.13–1.92, p = 0.004) and an increasing Charlson comorbidity index (CCI) score (OR 1.10, 95% CI 1.03–1.18), p = 0.003). Factors associated with 90-day readmission were HF (OR 1.51, 95% CI 1.08–2.11, p = 0.015), DM (OR 1.50, 95% CI 1.13–2.01, p = 0.006), AF (OR 1.40, 95% CI 1.00–1.94, p = 0.047) and increasing CCI score (OR 1.12, 95% CI 1.03–1.21, p = 0.006). Discharge to inpatient rehabilitation or skilled nursing facility (vs. home or home health) were associated with 90-day ED revisits and hospital readmissions. Patients who completed early (<30 days) outpatient stroke clinic follow-up had a lower likelihood of 90-day readmission (OR 0.68, 95% CI 0.52–0.90; p = 0.006).

Conclusion:

Patients with certain comorbidities including HF, DM, AF and those with a higher CCI score have a higher likelihood of a 90-day ED revisit and hospital readmission. Unplanned hospital readmissions may be preventable with early outpatient visits in a dedicated stroke clinic after discharge for AIS patients.

1 Introduction

Stroke remains to be a leading cause of death and disability worldwide (1), with outcomes in acute ischemic stroke (AIS) significantly influenced by a myriad of factors (2). These outcomes depend not only on acute patient care, including patient access to stroke diagnosis, treatment, and the rapid identification of treatment-related complications, but also on post-hospitalization care and secondary stroke prevention (35). Additionally, outcomes are shaped by patients' demographics (age, sex, etc.), comorbidities, stroke severity, post-discharge disposition, socioeconomic status and may be impacted by hospital revisits as well as early outpatient follow-up where stroke risk factors and etiology continue to be evaluated (3, 69).

Stroke is among the leading causes of unplanned hospital readmissions, which negatively impacts both healthcare costs and patient outcomes (10). In one systematic review and meta-analysis, it was shown that the readmission rate in patients with stroke was as high as 17% in the first month, and 42% in the year following the event (3), despite the advancements in the management of AIS. Therefore, limiting the rate of unplanned hospital and emergency department (ED) revisits, as a part of secondary stroke prevention for patients who suffer from AIS is of utmost importance.

The objective of this study was to evaluate the factors most likely associated with 90-day unplanned ED visits and hospital readmissions after being hospitalized for AIS. We also studied the impact of early transitional care outpatient follow-up by a centralized specialty stroke clinic.

2 Methods

2.1 Study setting and population

This was a retrospective study of all patients admitted primarily for a diagnosis of AIS from October 1st, 2022, to March 31st, 2024 to Emory Healthcare, the largest academic health system in the state of Georgia with locations primarily in metropolitan Atlanta. Data was collected using ICD-10 codes for ischemic strokes and retrieved directly from the electronic medical record. The following inclusion criteria were applied: (1) Adult patient population, who were (2) hospitalized with a diagnosis of AIS. We excluded patients who (1) left against medical advice, (2) were transferred to another acute care facility, (3) discharged to a long-term acute care or hospice or (4) had died prior to their discharge. For patients with multiple discharges, we only considered the earliest one. Readmission and ED revisits were categorized as “All-cause” and captured only those in our academic healthcare system. In our institution, telemedicine is conducted either via phone or video interviews primarily decided on by an agreement between patients and their providers. This study was approved by the institutional review board and the need for informed consent was waived due to the retrospective nature of the study.

2.2 Covariates

Baseline characteristics, lab results, inpatient metrics and post-discharge outpatient follow-up were assessed to identify factors associated with ED revisits and hospital readmission within 90 days after hospital discharge within the healthcare system. Early outpatient follow-up was defined as outpatient visits (telehealth or in-person) conducted within 30 days of being discharged from the hospital. Baseline characteristics included age, sex, race, and comorbid conditions were determined using the Charlson comorbidity index (CCI). This index is a scoring system used to predict the mortality risk for patients based on their disease or condition (1113). A score of zero indicates no comorbidities and as the score increases so does the predicted mortality rate (14). In this study, we also assessed various health conditions, such as diabetes mellitus (DM), heart failure (HF), hypertension (HTN), chronic kidney disease (CKD), hyperlipidemia, obesity, atrial fibrillation (AF) and the National Institutes of Health Stroke Scale (NIHSS) on index admission.

2.3 Statistical analysis

A database was created using an Excel spreadsheet to store and analyze the collected data. For continuous covariates, medians and IQR ranges were provided due to the non-normality assumption. For categorical covariates, frequency and proportion values were provided. For univariate comparisons, Wilcoxon rank sum tests and Chi-squared tests were performed on 90-day unplanned hospital and ED revisits for continuous and categorical covariates, respectively. Univariate and multiple logistic regression models were fitted to examine the association between 90-day unplanned hospital and ED revisits and covariates defined in the previous section. For univariate comparisons, if a covariate had missing values, the percentages and p-values were computed without missing values. For logistic regression models, a complete-case analysis approach was applied. For the multiple logistic regression model, the initial model included predictors of which p-values from univariate comparisons were <0.1. A stepwise model selection with both forward and backward selection was applied. The Akaike Information Criterion (AIC) was used as the selection criterion. Parameter estimates, 95% confidence intervals (CIs), and p-values were reported. All statistical analyses were performed in R, Version 4.3.2. P-values <0.05 were considered statistically significant.

3 Results

3.1 Emergency department revisits

Of 1,973 patients including in the study cohort, 464 (23.5%) had an all-cause ED revisit within 90 days. The median age was 68 [IQR 58, 77], 949 (48.1%) female, 1,146 (60.7%) African American, and 1,921 (97.4%) were from urban areas. History of HF, CKD, ESRD, DM, AF and obesity increased the likelihood of an ED revisit within 90 days in univariate analysis (Table 1). The final logistic regression model suggested that factors significantly associated with 90-day ED visit were history of HF (OR 1.46, 95% CI 1.11–1.93; p = 0.007), DM (OR 1.41, 95% CI 1.12–1.77; p = 0.003), AF (OR 1.47, 95% CI 1.13–1.92, p = 0.004), an increasing CCI score (OR 1.10, 95% CI 1.03–1.18), p = 0.003), and discharge to inpatient rehabilitation center (OR 1.74, 95% CI 1.22–2.47, p = 0.002) or skilled nursing facility (OR 1.66, 95% CI 1.13–2.45, p = 0.01) vs. home or home health (Table 2). Living in a rural (vs. urban) area was independently associated with a lower likelihood of 90-day ED visit (OR 0.29, 95% CI 0.10–0.82).

Table 1

Variable Levels (categorical) Marginal statistics No (1,509, 76.5%) Yes (464, 23.5%) p-value
Baseline demographic data
Age median, [IQR] 68 [58, 77] 68 [57, 76] 69.5 [60, 79] <0.001
Gender N, (%) Female 949 (48.1) 711 (47.1) 238 (51.3) 0.13
Male 1,024 (51.9) 798 (52.9) 226 (48.7)
Race and ethnicity N, (%) American Indian, Alaska Native 4 (0.2) 4 (0.3) 0 0.18
Asian 85 (4.5) 69 (4.8) 16 (3.5)
Black 1,146 (60.7) 847 (59.1) 299 (66.0)
Hispanic 76 (4.0) 59 (4.1) 17 (3.7)
Native Hawaiian, other Pacific Islander 1 (0.1) 1 (0.1) 0
Other 20 (1.1) 17 (1.2) 3 (0.7)
White 555 (29.41) 437 (30.5) 118 (26.0)
Rural N, (%) 52 (2.6) 48 (3.2) 4 (0.9) 0.01
Low-density lipoprotein median, [IQR] 94 [66, 124] 95 [67, 125] 89 [63, 123] 0.15
Length of stay median, [IQR] 4.3 [2.6, 8.1] 4.1 [2.3, 7.5] 5.2, [3.1, 9.1] <0.001
Charlson comorbidity score median, [IQR] 2.0 [0.0, 3.0] 2.0 [0.0, 3.0] 2.0 [2.0, 4.0] <0.001
Stroke education N, (%) 1,403 (71.1) 1,064 (70.5) 339 (73.1) 0.32
Comorbidity N , (%)
HF 471 (23.9) 302 (20.0) 169 (36.4) <0.001
CKD 545 (27.6) 368 (24.4) 177 (38.1) <0.001
ESRD 63 (3.2) 41 (2.7) 22 (4.7) 0.044
Diabetes 883 (44.7) 625 (41.4) 258 (55.6) <0.001
HTN 1,381 (70.0) 1,054 (69.8) 327 (70.5) 0.84
Obesity 376 (19.1) 271 (18.0) 105 (22.6) 0.03
AF 397 (20.1) 266 (17.6) 131 (28.2) <0.001
Hyperlipidemia N, (%) 1,306 (71.5) 1,008 (72.4) 298 (68.8) 0.17
HbA1c N, (%) <5.7 561 (42.1) 426 (42.1) 135 (41.8) 0.70
5.7–6.4 360 (27.0) 278 (27.50) 82 (25.4)
6.5–6.9 92 (6.9) 71 (7.0) 21 (6.5)
>6.9 321 (24.0) 236 (23.3) 85 (26.3)
NIHSS N, (%) 0 473 (24.8) 385 (26.5) 88 (19.5) <0.001
1–4 854 (44.8) 662 (45.5) 192 (42.5)
5–15 452 (23.7) 325 (22.4) 127 (28.1)
16–20 68 (3.6) 48 (3.3) 20 (4.4)
>20 59 (3.1) 34 (2.3) 25 (5.5)
Thrombectomy N, (%) 108 (5.5) 82 (5.4) 26 (5.6) 0.98
Discharge destination N, (%) Home/home health 1,459 (73.9) 1,158 (76.7) 301 (64.9) <0.001
Inpatient rehab 290 (14.7) 202 (13.4) 88 (19.0)
Skilled nursing facility 224 (11.4) 149 (9.9) 75 (16.2)

Demographics and comorbidities associated with ED revisits within 90 days.

AF, atrial fibrillation; CCI, Charlson comorbidity index; CKD, chronic kidney disease; DM, diabetes mellitus; ESRD, end stage renal disease; HF, heart failure; HTN, hypertension; IQR, interquartile range; NIHSS, national institutes of health stroke scale; OR, odds ratio. Bold values indicate statistical significance.

Table 2

Variable OR 95% CI p-value
AF 1.47 (1.13–1.92) 0.004
CKD 1.26 (0.97–1.62) 0.081
DM 1.41 (1.12–1.77) 0.003
HF 1.46 (1.11–1.93) 0.007
Increasing CCI 1.10 (1.03–1.18) 0.003
Rural areas 0.29 (0.10–0.82) 0.02
Discharge destination
Inpatient rehab 1.60 (1.20–2.15) 0.002
Skilled nursing facility 1.58 (1.14–2.18) 0.006
Home/Home health Reference

Multiple logistic regression after model selection for ED revisits within 90 days.

AF, atrial fibrillation; CCI, Charlson comorbidity index; CKD, chronic kidney disease; DM, diabetes mellitus; HF, heart failure; IQR, interquartile range; OR, odds ratio; N/A, not applicable. Bold values indicate statistical significance.

3.2 Hospital readmission

Of 1,973 patients, 263 (13.3%) had 90-day all-cause readmissions to the healthcare system, respectively. Length of stay, increasing age, CCI score, history of HF, CKD, DM, AF, hyperlipidemia, obesity, discharge to inpatient rehabilitation or skilled nursing facility, and NIH stroke scales were associated with hospital re-admission within 90 days in univariable analysis (Table 3). The final multiple logistic regression model suggested that HF (OR 1.51, 95% CI 1.08–2.11, p = 0.015), DM (OR 1.50, 95% CI 1.13–2.01, p = 0.006), AF (OR 1.40, 95% CI 1.00–1.94, p = 0.047), increasing CCI score (OR 1.12, 95% CI 1.03–1.21, p = 0.006) and discharge to inpatient rehabilitation center (OR 1.74, 95% CI 1.22–2.47, p = 0.002) or skilled nursing facility (OR 1.66, 95% CI 1.13–2.45, p = 0.01) were significantly associated with 90-day hospital readmission (Table 4).

Table 3

Variable Levels (categorical) Marginal statistics No (1,710, 86.7%) Yes (263, 13.3%) p-value
Baseline demographic data
Age Median, [IQR] 68 [58, 77] 67.5 [57, 77] 71 [61.5, 80] <0.001
Gender N, (%) Female 949 (48.1) 822 (48.1) 127 (48.3) 1.00
Male 1,024 (51.9) 888 (51.9) 136 (51.7)
Race and ethnicity N , (%) American Indian, Alaska Native 4 (0.2) 4 (0.3) 0 (0.0) 0.97
Asian 85 (4.5) 75 (4.6) 10 (3.9)
Black 1,146 (60.7) 988 (60.6) 158 (61.5)
Hispanic 76 (4.0) 65 (4.0) 11 (4.3)
Native Hawaiian, Other Pacific Islander 1 (0.1) 1 (0.1) 0 (0.0)
Other 20 (1.1) 18 (1.1) 2 (0.8)
White 555 (29.4) 479 (29.4) 76 (29.6)
Rural N, (%) 52 (2.6) 49 (2.9) 3 (1.1) 0.16
Low-density lipoprotein Median, [IQR] 94 [66, 124] 95 [67, 124] 86 [60.8, 128.3] 0.087
Length of stay Median, [IQR] 4.3 [2.6, 8.1] 4.2 [2.4, 7.8] 5.3 [3.1, 9.9] 0.001
Charlson comorbidity score Median [IQR] 2.0 [0.0, 3.0] 2.0 [0.0, 3.0] 3.0 [2.0, 5.0] <0.001
Stroke education N, (%) 1,064 (70.5) 1,217 (71.2) 186 (70.7) 0.94
Comorbidity N , (%)
HF 302 (20.0) 363 (21.2) 108 (41.1) <0.001
CKD 368 (24.4) 434 (25.4) 111 (42.2) <0.001
ESRD 41 (2.7) 49 (2.9) 14 (5.3) 0.055
DM 625 (41.4) 725 (42.40) 158 (60.1) <0.001
HTN 1,054 (69.8) 1,198 (70.1) 183 (69.6) 0.93
Obesity 271 (18.0) 312 (18.3) 64 (24.3) 0.024
AF 266 (17.6) 315 (18.4) 82 (31.2) <0.001
Hyperlipidemia 1,306 (71.5) 1,146 (72.4) 160 (65.6) 0.033
HbA1c N , (%) <5.7 561 (42.1) 492 (42.6) 69 (38.8) 0.067
5.7–6.4 360 (27.0) 321 (27.8) 39 (21.9)
6.5–6.9 92 (6.9) 76 (6.6) 16 (9.0)
>6.9 321 (24.0) 267 (23.1) 54 (30.3)
NIHSS N , (%) 0 473 (24.8) 431 (26.1) 42 (16.5) <0.001
1–4 854 (44.8) 749 (45.3) 105 (41.3)
5–15 452 (23.7) 370 (22.4) 82 (32.3)
16–20 68 (3.6) 58 (3.5) 10 (3.9)
>20 59 (3.1) 44 (2.7) 15 (5.9)
Thrombectomy N, (%) 108 (5.5) 91 (5.3) 17 (6.5) 0.54
Discharge destination N , (%) Home/home health 1,459 (73.9) 1,299 (76.0) 160 (60.8) <0.001
Inpatient rehab 290 (14.7) 236 (13.8) 54 (20.6)
Skilled nursing facility (SNF) 224 (11.4) 175 (10.2) 49 (18.6)

Demographics and comorbidities associated with hospital readmissions within 90 days.

AF, atrial fibrillation; CCI, Charlson comorbidity index; CKD, chronic kidney disease; DM, diabetes mellitus; ESRD, end stage renal disease; HF, heart failure; HTN, hypertension; IQR, interquartile range; NIHSS, national institutes of health stroke scale; OR, odds ratio. Bold values indicate statistical significance.

Table 4

Variable OR 95% CI p-value
HF 1.51 (1.08–2.11) 0.015
CKD 1.28 (0.94–1.75) 0.12
Diabetes 1.50 (1.13–2.01) 0.006
AF 1.40 (1.00–1.94) 0.047
Increasing Age 1.01 (0.99–1.02) 0.085
Increasing CCI 1.12 (1.03–1.21) 0.006
Discharge destination
Inpatient rehab 1.74 (1.22–2.47) 0.002
Skilled nursing facility 1.66 (1.13–2.45) 0.01
Home/Home health Reference

Multiple logistic regression after model selection for hospital readmission within 90 days.

AF, atrial fibrillation; CCI, Charlson comorbidity index; CKD, chronic kidney disease; DM, diabetes mellitus; HF, heart failure; IQR, interquartile range; OR, odds ratio; N/A, Not applicable. Bold values indicate statistical significance.

3.3 Outpatient follow-up

There were 424 (21.5%) patients who completed an outpatient stroke clinic follow-up within 30 days of discharge, including 72 patients (3.6%) who completed a telemedicine outpatient visit. Of those, 403 patients were seen in a stroke clinic and 31 in a general neurology clinic. The univariate logistic regression models suggested that the completion of a stroke clinic follow-up within 30 days of discharge was significantly associated with a lower likelihood of 90-day readmission (OR 0.68, 95% CI 0.52–0.90; p = 0.006). Patients who completed the first stroke clinic follow-up with a medical doctor compared to those seen by an advanced practitioner had lower odds of an ED revisit within 90 days, though not statistically significant (OR 0.82, 95% CI 0.23–2.91, p = 0.77). Similarly, those seen in-person had comparable odds compared to those seen via telemedicine (OR 0.92, 95% CI 0.48–1.75, p = 0.80), also not significant.

4 Discussion

We found that ED revisits and hospital readmissions within 90 days were associated with patient comorbidities including HF, AF, DM, increasing CCI score, and discharge destination. We also observed that early outpatient follow-up (within 30 days) in an outpatient dedicated stroke clinic was associated with a significant reduction in 90-day readmission rates.

Patients who suffer from AIS frequently have coexisting medical conditions such as HF (15), AF (16), DM (17) and HTN (18), all of which negatively impact patient outcomes, stroke severity, the rate of hospital revisits as well as the cost of care. For instance, patients with uncontrolled HTN at presentation often experience larger infarct volumes and smaller salvageable tissues (19), while those with DM more often experience early neurological deterioration (2) (defined as NIHSS change of ≥4 in the first 72 h). These not only manifest in a higher hospital revisit rate due to worse outcomes, but also in higher hospitalization costs (20). The impact of this is also captured utilizing the CCI scoring system, which estimates the 10-year survival rate based on comorbidity burden (14). One meta-analysis showed that patients with a CCI score >2 had a nearly fourfold increase in the risk of mortality [OR 3.80, 95% CI (1.20–12.01)] (21). Although we excluded patients who died before discharge, our results align with these results, as an increasing CCI score independently increased morbidity burden via unplanned ED and hospital revisits. In another study, it was shown a CCI score of 3 or more was an effective predictor of length of stay and hospital cost (22). These results underscore the necessity of a closer attention to this subset of patients, as recurrent readmissions not only translate clinically into a poor clinical outcome with reduced survival rates, but also contribute to increased healthcare costs (22, 23). Our findings are consistent with prior literature demonstrating a worse clinical outcome as well as hospitalization cost that corresponds to an increasing comorbidity burden (14, 20). Identifying these potential predictors serve as an opportunity to implement targeted interventions aimed at reducing readmission rates for patients with AIS. By recognizing individuals with higher risk, clinicians can plan on a closer outpatient follow-up and provide individualized discharge education to address these predictive factors. These strategies are expected to not only improve patient outcome by reducing recurrent hospital revisit rates, but also lowers healthcare costs.

One study showed that stroke patients with HF and chronic obstructive pulmonary disease who had an outpatient follow-up shortly after their hospital discharge were 21% less likely to be readmitted to the hospital [OR/HR 0.79, 95% CI (0.69–0.91), p = 0.001] (23). These outpatient visits serve as an opportunity to complete a comprehensive stroke evaluation, thus ensuring appropriate secondary stroke preventative measures, as well as address co-morbidities that are often associated with AIS. In a comprehensive meta-analysis of 47 randomized controlled trials, two main strategies were highlighted to help reduce hospital readmissions: (1) early interventions facilitating the transition from hospital to home, beginning before discharge, and (2) strategies reinforcing patient empowerment (24). Our study further emphasizes the importance of scheduling patients in the clinic, especially within 30 days and prior to their discharge, in preventing unplanned hospital revisits. Implementation of telemedicine visits to supplement in-person visits also helps in overcoming patient-centered barriers and unexpected cancellations due to weather changes, work commitments, caregiver and family unavailability, the lack of transportation, contagious illnesses or childcare responsibilities -all of which reinforce patient and caregiver empowerment.

While our study offers valuable insights with important clinical implications, several limitations need to be acknowledged. First, its retrospective nature could have introduced bias. Second, only 21.5% had outpatient follow-up visits within 30 days, including only 3.6% via telemedicine during the study period limiting a broader assessment of the impact from telemedicine use. Lastly, this study only captured ED revisits and inpatient readmissions within our healthcare system; while our academic healthcare system is the largest in the state of Georgia, hospital visits to other healthcare facilities were not included and therefore may have been underestimated especially in rural geographic areas.

5 Conclusion

Ischemic stroke patients with comorbid conditions including AF, DM, and HF, those with a higher CCI score, and discharge destination to an inpatient rehab or skilled nursing facility are associated with an increased likelihood of 90-day ED revisit or hospital readmission. Efforts to increase outpatient stroke clinic access within 30 days following ischemic stroke discharge may help reduce these 90-day ED revisits and readmissions for acute ischemic stroke patients.

Statements

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by Emory University Institutional Review Board. The studies were conducted in accordance with the local legislation and institutional requirements. The Ethics Committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants' legal guardians/next of kin due to the retrospective nature of the study with a low risk for patient harm.

Author contributions

AJ: Data curation, Visualization, Conceptualization, Investigation, Resources, Validation, Project administration, Writing – review & editing, Supervision, Writing – original draft, Methodology. JR: Writing – original draft, Visualization, Validation, Writing – review & editing, Investigation, Methodology, Supervision, Resources. TM: Formal analysis, Visualization, Data curation, Resources, Validation, Investigation, Software, Methodology, Writing – review & editing, Supervision, Writing – original draft, Conceptualization. JO: Writing – original draft, Resources, Visualization, Methodology. YW: Validation, Project administration, Conceptualization, Supervision, Writing – review & editing, Methodology, Investigation, Writing – original draft, Resources, Visualization, Software, Formal analysis. DS: Writing – original draft, Methodology, Visualization, Resources. HC: Writing – original draft, Visualization, Resources, Methodology. DB: Methodology, Resources, Visualization, Writing – original draft. LH: Resources, Visualization, Methodology, Writing – original draft. SB: Visualization, Methodology, Supervision, Conceptualization, Validation, Software, Resources, Writing – original draft, Investigation, Writing – review & editing. NK: Project administration, Visualization, Resources, Validation, Methodology, Investigation, Writing – review & editing, Conceptualization, Supervision, Writing – original draft. JCa: Writing – original draft, Visualization, Methodology, Resources. TW: Resources, Visualization, Writing – original draft, Methodology. JCo: Resources, Writing – original draft, Methodology, Visualization. KM: Writing – original draft, Visualization, Methodology, Resources. FN: Project administration, Validation, Data curation, Software, Methodology, Visualization, Resources, Conceptualization, Writing – review & editing, Investigation, Writing – original draft, Supervision.

Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Generative AI statement

The author(s) declare that no Gen AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2025.1683753/full#supplementary-material

Supplementary Figure S1

Area under the curve (ED revisits).

Supplementary Figure S2

Area under the curve (hospital readmissions).

References

  • 1.

    Feigin VL Brainin M Norrving B Martins SO Pandian J Lindsay P et al . World stroke organization: global stroke fact sheet 2025. Int J Stroke. (2025) 20:13244. 10.1177/17474930241308142

  • 2.

    Torres-Aguila NP Carrera C Muiño E Cullell N Cárcel-Márquez J Gallego-Fabrega C et al . Clinical variables and genetic risk factors associated with the acute outcome of ischemic stroke: a systematic review. J Stroke. (2019) 21:27689. 10.5853/jos.2019.01522

  • 3.

    Zhong W Geng N Wang P Li Z Cao L . Prevalence, causes and risk factors of hospital readmissions after acute stroke and transient ischemic attack: a systematic review and meta-analysis. Neurol Sci. (2016) 37:1195202. 10.1007/s10072-016-2570-5

  • 4.

    Terman SW Reeves MJ Skolarus LE Burke JF . Association between early outpatient visits and readmissions after ischemic stroke. Circ Cardiovasc Qual Outcomes. (2018) 11:e004024. 10.1161/CIRCOUTCOMES.117.004024

  • 5.

    Leppert MH Sillau S Lindrooth RC Poisson SN Campbell JD Simpson JR . Relationship between early follow-up and readmission within 30 and 90 days after ischemic stroke. Neurology. (2020) 94:e1249e58. 10.1212/WNL.0000000000009135

  • 6.

    Donkor ES . Stroke in the 21(st) century: a snapshot of the burden, epidemiology, and quality of life. Stroke Res Treat. (2018) 2018:3238165. 10.1155/2018/3238165

  • 7.

    Man S Bruckman D Tang AS Uchino K Schold JD . The association of socioeconomic status and discharge destination with 30-day readmission after ischemic stroke. J Stroke Cerebrovasc Dis. (2021) 30:106146. 10.1016/j.jstrokecerebrovasdis.2021.106146

  • 8.

    Chen W Li D . Comorbidity and outcomes among hospitalized patients with stroke: a nationwide inpatient analysis. Front Neurol. (2023) 14:1217404. 10.3389/fneur.2023.1217404

  • 9.

    Spiegler KM Irvine H Torres J Cardiel M Ishida K Lewis A et al . Characteristics associated with 30-day post-stroke readmission within an academic urban hospital network. J Stroke Cerebrovasc Dis. (2024) 33:107984. 10.1016/j.jstrokecerebrovasdis.2024.107984

  • 10.

    Abreu P Correia M Azevedo E Sousa-Pinto B Magalhães R . Rapid systematic review of readmissions costs after stroke. Cost Eff Resour Alloc. (2024) 22:22. 10.1186/s12962-024-00518-3

  • 11.

    Hall RE Porter J Quan H Reeves MJ . Developing an adapted Charlson comorbidity index for ischemic stroke outcome studies. BMC Health Serv Res. (2019) 19:930. 10.1186/s12913-019-4720-y

  • 12.

    Cho H Kim MH Kim HJ Park JY Ryu DR Lee H et al . Development and validation of the modified charlson comorbidity index in incident peritoneal dialysis patients: a national population-based approach. Perit Dial Int. (2017) 37:94102. 10.3747/pdi.2015.00201

  • 13.

    Jesus APS Okuno MFP Campanharo CRV Lopes M Batista REA . Association of the Charlson index with risk classification, clinical aspects, and emergency outcomes. Rev Esc Enferm USP. (2022) 56:e20200162. 10.1590/1980-220x-reeusp-2020-0162

  • 14.

    Charlson ME Pompei P Ales KL MacKenzie CR . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. (1987) 40:37383. 10.1016/0021-9681(87)90171-8

  • 15.

    Tai YH Chang CC Yeh CC Sung LC Hu CJ Cherng YG et al . Long-term risk of stroke and poststroke outcomes in patients with heart failure: two nationwide studies. Clin Epidemiol. (2020) 12:123544. 10.2147/CLEP.S261179

  • 16.

    Yaghi S Hinduja A Bianchi N . Predictors of major improvement after intravenous thrombolysis in acute ischemic stroke. Int J Neurosci. (2016) 126:679. 10.3109/00207454.2014.1002611

  • 17.

    Geng HH Wang Q Li B Cui BB Jin YP Fu RL et al . Early neurological deterioration during the acute phase as a predictor of long-term outcome after first-ever ischemic stroke. Medicine. (2017) 96:e9068. 10.1097/MD.0000000000009068

  • 18.

    Gill D Cox T Aravind A Wilding P Korompoki E Veltkamp R et al . A fall in systolic blood pressure 24 hours after thrombolysis for acute ischemic stroke is associated with early neurological recovery. J Stroke Cerebrovasc Dis. (2016) 25:153943. 10.1016/j.jstrokecerebrovasdis.2016.03.002

  • 19.

    Cipolla MJ Liebeskind DS Chan SL . The importance of comorbidities in ischemic stroke: impact of hypertension on the cerebral circulation. J Cereb Blood Flow Metab. (2018) 38:212949. 10.1177/0271678X18800589

  • 20.

    Liu CH Wei YC Lin JR Chang CH Chang TY Huang KL et al . Initial blood pressure is associated with stroke severity and is predictive of admission cost and one-year outcome in different stroke subtypes: a SRICHS registry study. BMC Neurol. (2016) 16:27. 10.1186/s12883-016-0546-y

  • 21.

    Rashid M Kwok CS Gale CP Doherty P Olier I Sperrin M et al . Impact of co-morbid burden on mortality in patients with coronary heart disease, heart failure, and cerebrovascular accident: a systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. (2017) 3:2036. 10.1093/ehjqcco/qcw025

  • 22.

    Liu H Song B Jin J Liu Y Wen X Cheng S et al . Length of stay, hospital costs and mortality associated with comorbidity according to the charlson comorbidity index in immobile patients after ischemic stroke in China: a national study. Int J Health Policy Manag. (2022) 11:17807. 10.34172/ijhpm.2021.79

  • 23.

    Bilicki DJ Reeves MJ . Outpatient follow-up visits to reduce 30-day all-cause readmissions for heart failure, copd, myocardial infarction, and stroke: a systematic review and meta-analysis. Prev Chronic Dis. (2024) 21:E74. 10.5888/pcd21.240138

  • 24.

    Braet A Weltens C Sermeus W . Effectiveness of discharge interventions from hospital to home on hospital readmissions: a systematic review. JBI Database System Rev Implement Rep. (2016) 14:10673. 10.11124/jbisrir-2016-2381

Summary

Keywords

unplanned hospital revisits, emergency department revisits, acute ischemic stroke, telemedicine, prevention

Citation

Jumah A, Ro J, Ma T, Owens J, Wu Y, Starnes D, Christopher H, Blanke D, Henriquez L, Belagaje SR, Kvantaliani N, Cabral J, Walczak T, Collier J, Mack K and Nahab F (2025) Predictors of unplanned hospital readmissions and emergency department revisits in patients with acute ischemic stroke. Front. Neurol. 16:1683753. doi: 10.3389/fneur.2025.1683753

Received

11 August 2025

Accepted

01 October 2025

Published

21 October 2025

Volume

16 - 2025

Edited by

Aleksandras Vilionskis, Vilnius University, Lithuania

Reviewed by

Luis Rafael Moscote-Salazar, Colombian Clinical Research Group in Neurocritical Care, Colombia

Kevin Spiegler, New York University, United States

Updates

Copyright

*Correspondence: Ammar Jumah

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics